// App-Quantinova.ai

2088 : Achieving Systemic Lupus Erythematosus Disease Control or Low Lupus Disease Activity State Is Associated with Lower Rates of Organ Damage: Results from the Hopkins Lupus Cohort

Researchers

Presenter

  • Jacob N. Hunnicutt

Principal Investigators

  • Mary E. Georgiou

  • Anna Richards

  • Holly Quasny

  • Laurence S Magder

  • Daniel W. Goldman

  • Michelle Petri

Medical Centers

  • GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, USA

  • GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom

  • GlaxoSmithKline, Clinical Sciences, Research Triangle Park, NC

  • University of Maryland Department of Epidemiology and Public Health, Baltimore, MD

  • Johns Hopkins University School of Medicine, Devision of Rheumatology, Baltimore, MD

Locations

  • Turkmenistan

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Prednisone

Outcome

  • N/A

Study Design

  • Observational

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved